Theravance Biopharma, Inc. (TBPH) — SEC Filings
Theravance Biopharma, Inc. (TBPH) — 45 SEC filings. Latest: 10-Q (May 7, 2026). Includes 21 8-K, 10 SC 13G/A, 7 10-Q.
View Theravance Biopharma, Inc. on SEC EDGAR
Overview
Theravance Biopharma, Inc. (TBPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: On December 8, 2025, Theravance Biopharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." Specific details regarding material events or financial updates are not elaborated upon in the provided text, but the filing indicates a standard
Sentiment Summary
Across 45 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 41 neutral. The dominant filing sentiment for Theravance Biopharma, Inc. is neutral.
Filing Type Overview
Theravance Biopharma, Inc. (TBPH) has filed 7 10-Q, 21 8-K, 2 DEF 14A, 2 10-K, 10 SC 13G/A, 2 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (45)
Risk Profile
Risk Assessment: Of TBPH's 30 recent filings, 0 were flagged as high-risk, 7 as medium-risk, and 23 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $61,573,000 |
| Net Income | $44,870,000 |
| EPS | $0.89 |
| Debt-to-Equity | 0.17 |
| Cash Position | $174,773,000 |
| Operating Margin | -38.4% |
| Total Assets | $415,460,000 |
| Total Debt | $72,931,000 |
Key Executives
- Eran Broshy
- James Kelly
- Laurie Smaldone Alsup
- Rick E Winningham
- Andrew M. Weiss Ph.D.
Industry Context
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies often rely on strategic collaborations and partnerships to share risk and leverage expertise. The market for respiratory therapies, where Theravance operates with YUPELRI, is competitive, with ongoing innovation and patent expirations influencing market dynamics.
Top Tags
8-k (7) · financial-reporting (5) · 8-K (5) · financials (5) · filing (3) · corporate-filing (3) · sec-filing (2) · Biopharma (2) · Earnings (2) · Cash Flow (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $44.87M | For the nine months ended September 30, 2025, a swing from a $40.89M net loss in 2024. |
| Net Gain on Realized Contingent Milestone and Royalty Assets | $75.14M | Key driver of profitability for the nine months ended September 30, 2025. |
| Total Revenues | $61.57M | For the nine months ended September 30, 2025, up from $45.63M in 2024. |
| Licensing Revenue | $7.5M | Milestone payment from Viatris due to YUPELRI's China approval in June 2025. |
| Cash and Cash Equivalents | $174.77M | As of September 30, 2025, significantly up from $37.80M at December 31, 2024. |
| Net Cash Provided by Operating Activities | $244.61M | For the nine months ended September 30, 2025, a substantial increase from a $10.63M use in 2024. |
| Total Shareholders' Equity | $232.68M | As of September 30, 2025, an increase from $175.55M at December 31, 2024. |
| Basic Net Income Per Share | $0.89 | For the nine months ended September 30, 2025, compared to $(0.84) in 2024. |
| Loss from Operations | $17.2M | for the six months ended June 30, 2025, indicating reliance on non-operating gains for net income |
| Outstanding Ordinary Shares | 50,361,296 | as of August 1, 2025 |
| Commission File Number | 001-36033 | Identifies the company's filing with the SEC |
| I.R.S. Employer Identification Number | 98-1226628 | Tax identification number for the company |
| Cash per share | $1.00 | Amount shareholders will receive upon acquisition. |
| Other Assets Noncurrent | 50001000 | Reported value for noncurrent other assets. |
| Other Assets Noncurrent (Previous Period) | 49471000 | Comparative value for noncurrent other assets. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Theravance Biopharma, Inc. (TBPH)?
Theravance Biopharma, Inc. has 45 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 10 SC 13G/A, 7 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TBPH filings?
Across 45 filings, the sentiment breakdown is: 3 bullish, 1 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Theravance Biopharma, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Theravance Biopharma, Inc. (TBPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Theravance Biopharma, Inc.?
Key financial highlights from Theravance Biopharma, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TBPH?
The investment thesis for TBPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Theravance Biopharma, Inc.?
Key executives identified across Theravance Biopharma, Inc.'s filings include Eran Broshy, James Kelly, Laurie Smaldone Alsup, Rick E Winningham, Andrew M. Weiss Ph.D..
What are the main risk factors for Theravance Biopharma, Inc. stock?
Of TBPH's 30 assessed filings, 0 were flagged high-risk, 7 medium-risk, and 23 low-risk.
What are recent predictions and forward guidance from Theravance Biopharma, Inc.?
Forward guidance and predictions for Theravance Biopharma, Inc. are extracted from SEC filings as they are enriched.